Information about Crixivan (Indinavir)
Crixivan, with the generic name indinavir, is an antiretroviral medication used to treat HIV-1 infection. It is a protease inhibitor that works by blocking the protease enzyme, which is crucial for the replication of HIV. By inhibiting this enzyme, Crixivan helps to reduce the viral load in the body and slow the progression of HIV infection.
Product Highlights
- As part of a combination antiretroviral therapy for the treatment of HIV-1 infection in adults and pediatric patients.
Key Ingredient
Key Benefits
- Helps to significantly reduce HIV-1 viral load and improve immune system function when used in combination with other antiretrovirals.
- Proven to be effective in long-term management of HIV-1 infection when used as part of a comprehensive treatment regimen.
- Available in capsule form for oral administration.
Direction of Use
- Taken orally, with or without food.
- The usual dosage is 800 mg every 8 hours, typically three times daily. Adherence to dosing schedule is crucial for efficacy and to reduce the risk of resistance.
Safety Concerns
- Can cause kidney stones or renal impairment; patients should stay well-hydrated to help prevent these issues.
- May interact with a range of other medications, including those that affect liver enzymes (CYP3A4). Monitoring and adjustments may be necessary.
- Possible side effects may include nausea, diarrhea, and abdominal discomfort.
Avoid Crixivan (Indinavir) If
- Avoid if there is a known hypersensitivity to indinavir or any component of the formulation.
- Use is not recommended in patients with severe renal impairment due to the risk of accumulation and increased side effects.
- Avoid use with drugs that significantly affect CYP3A4 enzyme activity unless carefully monitored or alternative treatments are considered.
